Saturday 17 October 2026
Export KZIA’s income statement to Excel — free account
Novogen Limited
KZIA Healthcare Biotechnology
Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
7.25
0.15
−2.03%
Follow KZIA
| Jun '16 | Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 2 | 2 | 4 | 2 | 4 | 2 | 4 | 3 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.53 | (5.85) | 0.47 | (0.81) | (1.12) | 3.87 | (2.16) | (5.95) | (12.62) | (39.89) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
11.57 | (12.32) | 1.25 | (2.73) | (5.40) | 1.13 | (9.40) | (14.57) | (32.55) | (98.68) |
Beneish M-Score |
3.24 | 34.34 | (2.16) | 6.06 | (3.94) | 10.28 | — | 5.71 | 84.52 | (9.60) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 1.72 | 0.27 | 0.07 | 0.02 | 0.08 |
EV/Operating CF |
1.64 | 0.30 | 0.17 | 0.19 | 0.38 | 0.87 | 0.13 | 0.06 | 0.03 | 0.10 |
EV/FCF |
1.58 | 0.29 | 0.17 | 0.19 | 0.38 | 0.87 | 0.13 | 0.06 | 0.03 | 0.10 |
Quick Ratio |
23.50 | 3.48 | 2.18 | 3.76 | 2.00 | 3.32 | 1.59 | 1.21 | 0.22 | 0.32 |
Current Ratio |
23.81 | 3.62 | 2.38 | 3.95 | 2.10 | 3.53 | 1.62 | 1.42 | 0.24 | 0.35 |
Net Debt/EBITDA |
3.06 | 1.66 | 6.97 | 0.71 | 0.79 | 5.44 | 0.24 | 0.15 | 0.04 | 0.30 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.01% | 6.40% | 2.94% | 6.53% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.15 | (0.06) | (0.05) |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.06 | 0.05 | 0.39 | 0.00 | 0.00 | 0.10 | 0.14 |
Operating CF/Net income |
0.99 | 1.07 | 1.43 | 0.65 | 0.71 | 1.08 | 0.92 | 0.74 | 0.36 | 0.64 |
Capex/Depreciation |
(0.81) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(52.68) | (13.21) | (21.08) | (89.31) | (180.36) | (149.21) | (12,456.40) | (1,085.08) | — | — |
| (41.00%) | (24.51%) | (27.52%) | (58.60%) | (85.26%) | (33.32%) | (85.55%) | (127.36%) | (2,275.77%) | 224.48% | |
| (39.27%) | (21.22%) | (19.14%) | (39.72%) | (54.66%) | (21.37%) | (52.01%) | (62.24%) | (106.23%) | (148.30%) | |
ROIC |
(1,515.06%) | (58.03%) | (11.29%) | (62.05%) | (141.33%) | (38.58%) | (119.30%) | (175.20%) | 0.00% | 0.00% |
Return on Tangible Assets |
(36.28%) | (73.15%) | (112.37%) | (182.95%) | (223.19%) | (39.98%) | (843.26%) | (638.01%) | 136.26% | 227.02% |
Average Days of Receivables |
178.90 | 6,248.17 | 7,775.33 | 398.98 | 465.22 | 2.01 | 1,229.08 | 61,415.93 | 570.57 | 18.83 |
Research and Development Expense of Revenue |
2,436.91% | 4,472.78% | 8,209.97% | 413.78% | 894.92% | 95.49% | 74,963.27% | 67,164.74% | 697.16% | 385.37% |
Selling, General and Administrative Expense of Revenue |
1,418.94% | 3,118.43% | 4,702.17% | 241.88% | 347.80% | 46.12% | 16,701.53% | 37,039.10% | 544.05% | 458.70% |
Intangible Assets out of Total Assets |
0.02 | 0.44 | 0.52 | 0.64 | 0.54 | 0.38 | 0.57 | 0.61 | 0.71 | 0.18 |
Share Based Compensation of Revenue |
91.62% | 207.67% | 138.57% | 15.74% | 24.71% | 4.18% | 6,200.00% | 5,001.92% | 21.38% | 34.35% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(111.78%) | (211.39%) | (91.93%) | (4.84%) | (0.14%) | (0.04%) | (0.09%) | (0.37%) | (1.96%) | (3.44%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
6.51 | 2.01 | 0.95 | 9.73 | 4.88 | 48.35 | 0.07 | 0.04 | 3.10 | 1.12 |
Operating CF per Share |
(192.23) | (92.10) | (69.37) | (41.76) | (40.49) | (28.93) | (62.34) | (27.68) | (11.91) | (7.85) |
Capex per Share |
(8.38) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(200.60) | (92.26) | (69.37) | (41.76) | (40.49) | (28.93) | (62.34) | (27.68) | (11.91) | (7.85) |
Cash per Share |
536.77 | 116.43 | 47.70 | 33.79 | 40.28 | 87.60 | 20.16 | 9.57 | 2.06 | 2.57 |
Shareholders Equity per Share |
544.44 | 204.08 | 154.11 | 88.28 | 64.92 | 120.20 | 51.05 | 22.01 | (12.46) | (4.91) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
544.44 | 204.08 | 154.11 | 88.28 | 64.92 | 120.20 | 51.05 | 22.01 | (12.46) | (4.91) |
Free Cash Flow |
(17.15) | (8.64) | (6.71) | (4.80) | (5.92) | (6.81) | (16.51) | (10.20) | (6.28) | (8.60) |
Working Capital |
44.80 | 10.63 | 4.17 | 4.02 | 3.75 | 15.74 | 2.12 | 2.16 | (12.89) | (5.91) |
Capital Expenditures |
(0.72) | (0.01) | — | — | — | — | — | — | — | — |
Net Current Asset Value |
44.59 | 6.72 | 0.25 | 0.38 | 1.15 | 6.84 | (6.32) | (3.54) | (16.69) | (6.11) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.29 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.09 | 2.90 | 1,499.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(18.55%) | (28.79%) | (34.37%) | (34.21%) | (38.49%) | (13.92%) | (82.02%) | (79.40%) | 124.01% | 372.97% |
Accounts Receivable Turnover |
2.86 | 0.11 | 0.04 | 0.70 | 0.67 | 23.44 | 0.30 | 0.01 | 0.63 | 0.94 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Receivables |
0.19 | 1.74 | 2.59 | 1.59 | 1.07 | 0.49 | 0.06 | 1.35 | 2.59 | 1.31 |
Average Payables |
1.52 | 1.60 | 1.51 | 1.43 | 1.80 | 3.01 | 3.21 | 2.82 | 6.40 | 8.22 |
Average Assets |
42.14 | 37.90 | 24.46 | 18.49 | 15.32 | 29.45 | 34.38 | 22.13 | 16.53 | 9.04 |
Average Common Equity |
40.36 | 32.83 | 17.01 | 12.54 | 9.82 | 18.88 | 20.90 | 10.82 | 0.77 | (5.97) |
Columns are period end dates · fundamentals updated 2 Oct 2026